Medicament for treating thrombocytolytic purpura

Abstract

The invention provides a medicament for treating thrombocytolytic purpura, which comprises the following raw materials by weight part: 15-25 parts of rhizoma smilacis glabrae, 20-30 parts of honeysuckle, 10-20 parts of radix arnebiae seu lithospermi, 10-20 parts of rehmannia root, 10-20 parts of white mulberry root-bark, 25-35 parts of oyster, 10-20 parts of clerodendrum bungei, 10-20 parts of yellow celery and 5-15 parts of cicada slough. In the invention, the natural herbal drugs capable of clearing away heat and toxic materials, activating blood and dissolving stasis, cooling and nourishingblood and stopping bleeding, removing water and eliminating swellings are selected from the medicinal treasury of China, and play roles of clearing away heat, cooling the blood, stopping the bleeding, eliminating spots, activating blood and dissolving stasis, improving the microcirculation, dredging channels, diminishing pain, and the like according to a Chinese medicine theory formula. The medicament does not contain any chemical drugs, thereby being innoxious to human bodies; and the medicament is convenient to take, can enhance the resistance and the immunity of organisms and relieve pains of patients, and has obvious curative effect.

Description

technical field [0001] The invention relates to a medicine, in particular to a traditional Chinese medicine for treating thrombocytopenic purpura, and belongs to the field of biotechnology. Background technique [0002] Thrombocytopenic purpura is a common hemorrhagic disease related to platelets. The clinical manifestations are skin bleeding (such as petechiae and ecchymosis), mucosal bleeding (such as nose, gum and oral bleeding), and internal bleeding. (such as gastrointestinal tract and urinary, reproductive system bleeding). Laboratory features include thrombocytopenia, prolonged bleeding time, poor clot retraction, and positive capillary fragility test. The disease is divided into primary and secondary two. Primary (that is, unknown cause) thrombocytopenic purpura mostly occurs in children and adolescents, mostly young women. The occurrence of this disease is related to immunity, and the spleen also plays an important role in the destruction of platelets. If the pl...

AI Technical Summary

Problems solved by technology

The existing commercially available traditional Chinese medicines have large individual differences in human body, some people are suitable for some people, and some people are difficult to apply, or even have no effect. Therefore, it is difficult to generally obtain ideal therapeutic effects